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Protein misfolding and aggregation are
now well-recognized processes that
often lead to amyloid ﬁbril formation
(amyloidosis). Because these events are
coupled with many types of human
disease, the ﬁeld of protein amyloidosis
is under intense investigation. In the
amyloid ﬁbrils, the proteins adopt cross
b-pleated sheet structures with distinct
tinctorial and morphological properties,
and typically consist of long, unbran-
ched ﬁlaments that bind to diagnostic
dyes such as Thioﬂavin-T and Congo
Red (Temussi et al., 2003). There are
currently 24 proteins that produce
amyloid ﬁbrils associated with human
disease (Westermark et al., 2002), in-
cluding the Ab of Alzheimer’s disease,
prion of transmissible spongiform ence-
phalopathies, amylin of maturity-onset
diabetes, transthyretin of familial amy-
loidosis, huntingtin of Huntington’s
disease, and a-synuclein of Parkinson’s
disease. Albeit these proteins have very
different primary sequences, molecular
sizes, and folded tertiary structures, they
all produce amyloidﬁbrils.Amyloidosis
may also be a general property for all
proteins, since de novo designed pep-
tides and other naturally occurring pro-
teins not associated with human disease
(such as myoglobin) (Fandrich et al.,
2001) can be encouraged to aggregate as
amyloid ﬁbrils.
Despite the plethora of research,
details about the molecular mecha-
nisms of amyloidosis are still lacking.
Most scientists agree that unraveling
the chemical mechanisms is absolutely
essential for the development of spe-
ciﬁc inhibitors to prevent amyloidosis
in humans. The most obvious missing
details are high-resolution structural
data, particularly regarding the soluble
b-sheet aggregates and the amyloid
ﬁbril structures. Given that amyloid
ﬁbrils are not amenable to standard
x-ray crystallography (i.e., they do not
form crystals), lower-resolution analy-
tical techniques such as x-ray ﬁbril
diffraction, negative stain electron mi-
croscopy, and atomic force microscopy
have been employed. Although these
methods have provided valuable data
about the ﬁbril morphology, including
the discovery of ‘‘toxic’’ intermediates
such as the ‘‘protoﬁbrils’’ (Caughey
and Lansbury, 2003), they cannot
provide critical atomic level structural
information, such as what amino acids
are interacting during the aggregation
processes and whether or not the ﬁbrils
adopt unique, folded structures. In this
regard, the work presented by the
Tycko and Meredith research groups
in this issue makes an important con-
tribution about the Ab ﬁbril structure of
Alzheimer’s disease. These research
groups have excellent track records
with handling the Ab peptide and were
the ﬁrst to demonstrate that the peptide
adopts the rare parallel b-sheet organ-
ization in the amyloid ﬁbrils.
The recent ﬁnding that solid-state
NMR spectroscopy is applicable to
amyloid ﬁbril structure determination
represents a timely and signiﬁcant
breakthrough (Tycko, 2003). For bio-
molecules, solid-state NMR has unique
capabilities, in that it can be used with
samples of limited solubility that often
precipitate as noncrystalline solids.
Solid-state NMR can provide accurate
distances and torsion angles between
site-speciﬁc 15N- and/or 13C-labeled
atoms, and, under certain conditions,
the NMR constraints can generate
structural models on par with those
obtained by solution NMR and x-ray.
Solid-state NMR is likewise a rapidly
growing ﬁeld, and studies of uniformly
or speciﬁcally labeled samples have
provided important information about
membrane-bound peptide channels and
the active sites of other membrane pro-
teins (Thompson, 2002), both of which
are systems not amenable to solution
NMR or x-ray.
The predominate forms of the Al-
zheimer’s Ab peptide are the 40-residue
Ab(1–40) and 42-residue Ab(1–42).
The earliest solid-state NMR studies
utilized peptide fragments composed of
regions important for amyloidosis, such
as the Ab(34–42) and Ab(16–22) pep-
tides, in which both form the anti-
parallel b-sheet as the major structural
motif. However, solid-state NMR stud-
ies of the longer 35-residue Ab(10–35)
and native Ab(1–40) peptides found
different results that were consistent
with in-register parallel b-sheet struc-
tures. The overall conclusion was that
accurate structural models must use
constraints obtained from the longer,
full-length Ab peptides, and that des-
pite the common cross b-pleated sheet
motif, speciﬁc structural details can be
sequence dependent. Nonetheless, the
parallel versus antiparallel variation
was a conundrum, since the shorter
Ab peptides still form classic amyloid
ﬁbrils based on Congo Red and elec-
tron microscopy.
As described in this issue, Gordon
et al. contemplated that peptide amphi-
philicity may inﬂuence the parallel
versus antiparallel orientation. Inspec-
tion of the Ab primary sequence reveals
that the Ab(16–22) and Ab(34–42)
peptides are nonamphiphilic, whereas
the Ab(10–35) and Ab(1–40) are am-
phiphilic. Additionally, the Ab(1–40)
peptide has surfactant properties and
forms micelles. Amphiphilicity would
stabilize the parallel b-sheet orienta-
tion and nonamphiphilicity the antipar-
allel, possibly by way of hydrogen-
bonding or electrostatic interactions
between oppositely charged side chains
or termini.
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To test this hypothesis, the Ab(16–
22) peptide was made amphiphilic by
attaching a long hydrophobic chain to
one end of the molecule (Scheme 1).
This objective was fulﬁlled by acyla-
tion of the N-terminus with octanoic
acid (CH3(CH2)6COOH), which in-
creased the peptide’s amphiphilicity
as measured from its stability at the
air-water interface, but did not reduce
its ability to form amyloid ﬁbrils. Based
on electron microscopy and Congo
Red, the modiﬁed octanoyl-Ab(16–
22) forms amyloid ﬁbrils that are
indistinguishable from those of un-
modiﬁed Ab(16–22). Without a doubt,
the hypothesis was proven accurate by
solid-state NMR with peptides contain-
ing 13C- and 15N-labels at strategic
sites, where the octanoyl-Ab(16–22)
formed parallel b-sheets and the
Ab(16–22) antiparallel b-sheets. For
consistency, the NMR methods em-
ployed were identical to those used
previously by the same group for
generating the Ab(1–40) peptide model
(Petkova et al., 2002), which included a
combination of low-precision (line-
widths and chemical shifts) and high-
precision (distances and torsion angles)
constraints. The labeling and dilution
strategy utilized four different peptide
mixtures and exempliﬁes the experi-
ence these groups have in studying the
Ab by solid-state NMR.
The work of Gordon et al. in this
issue has several important implica-
tions; notably, that peptide amphiphi-
licity is a critical parameter for
controlling the b-sheet organization of
amyloid ﬁbrils. This provides a ration-
ale for the proclivity toward parallel or
antiparallel arrangements and, more
importantly, that amyloid-forming pro-
teins may each adopt unique ﬁbril
structures that are only visible by
high-resolution techniques such as
NMR. The unique ﬁbril structures and
the importance of amphiphilicity sug-
gest that speciﬁc compounds could be
targeted toward inhibiting amyloidosis
of a single or select group of proteins,
possibly by altering the brain micro-
environment in a manner to prevent
formation of the native parallel ar-
rangement. Related approaches with
modulating the peptide amphiphilicity
has been used in the design of tertiary
and supramolecular structures and may
also be useful in the development of
self-assembling, nanoscale materials.
In closing, the article by Gordon
et al. in this issue clearly shows that
high-resolution structure determination
is urgently needed in the amyloid re-
search area, and that solid-state NMR
has emerged as an indispensable tool in
this endeavor.
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